In addition to an altered metabolic phenotype, inflammation has been reported to play a significant role in the progression and treatment response of OAC tumours, whereby elevated levels of pro-inflammatory mediators such as LIF, C3a, C4a and IL-1β have been associated with poor treatment response8,9,11. The gene discussed is IL1B; the disease is neoplasm.